FierceBiotech recognizes Recursion as the #2 Biotech IPO of 2021!

March 24, 2022

Recursion dazzled investors with a tantalizing pitch: We are a biotech scaling more like a tech company.

The potential to boost the scale and efficiency of drug development by automating wet labs and applying machine learning to the resulting data led investors to hand Recursion $502 million to take four drugs into phase 2 and advance six other programs up to the cusp of the clinic.

The company has advanced its internal pipeline while continuing business development activities.

Read the Top 10 Biotech IPO’s Special Report Here »